Immunomedics, Inc. kicked off the trading day on 08/26/19 with a price decrease of -0.84%, equivalent to -$0.11 relative change for the day. Taking a more long-term approach, IMMU had a 52-week range of $11.55 to $26.99. At the time of this article’s publishing, this stock is trading at $13.05 after starting the trading session at $13.45. Moving on, the stock has demonstrated a 52-week change amounting to 346.74, alongside an S&P500 52-Week Change of 278.65. At the time of writing, this stock’s 50-day Moving Average stands at $14.32, while the 200-day Moving Average of this stock is currently $15.88.
Currently, this company’s share volume is sitting at $2,198,674, but has maintained average daily volume of $2.28M. This stock has generated an average Year to Date volume of $2.75 million, alongside an average 20-day volume of $1.81 million. This publicly-traded company’s shares outstanding now amounts to $198.69 million, simultaneously with a float of $175.60 million. The organization now has a market capitalization sitting at $2.59 billion.
Immunomedics, Inc.(IMMU) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Immunomedics, Inc.’s current insider ownership accounts for 7.19%, in contrast to 90.90% institutional ownership. According to the most recent latest insider trade that took place on Jun 28 this organization’s Director bought 250,000 at the rate of 13.84, making the entire transaction hit 3,460,000 in total value, affecting insider ownership by 21,000,000. Preceding that transaction, on Jun 27 Company’s Director bought 350,000 at a price of 13.68, making the whole transaction’s value amount to 4,788,000. This particular insider is now the holder of 20,750,000 in total.
If we take a glance at the Ownership summary of Immunomedics, Inc.’s stock, 233 Institutional holders make up 89.51% of its total stock ownership. All together, they are the legal holders of 171,833,661 shares, which are valued at about $2,261,330,979 in total. If we focus on the top 3 stockholders for this publicly-traded organization, AVORO CAPITAL ADVISORS LLC owns 21.0 million shares, with VANGUARD GROUP INC in 2nd place owning 15.15 million shares and BLACKROCK INC. in third place with total ownership of 13.8 million shares.
Immunomedics, Inc. (IMMU) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Mar-19, the organization reported -$0.46 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.38) by $0.08.
The corporation racked down revenue of $0.39million for the previous financial quarter, compared to the mean analyst estimate of $4.27 million. This company achieved a net margin of -83149.74 while generating a return on equity of -153.93. Immunomedics, Inc.’s full-quarter revenue decreased by -100.0%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
Immunomedics, Inc.’s EPS increase for this current 12-month fiscal period is 53.10%, and is forecasted to reach 8.50% in the upcoming year.
Additional Trading Performance Indicators
The company has managed to achieve an average true range (ATR) of 0.66. Alongside those, its Beta score is 2.03.
Plus, this company’s price to book ratio for the last three-month fiscal period reported is 21.75, whereas its price to cash per share for the last quarter landed at 2.18.
In the same vein, IMMU’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -1.36, a figure that is expected to reach -0.37 in the next reported quarter, and analysts expect it will be 8.50% at the market close of one year from today’s date.